Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Q-004
- Development stage
- Preclinical
- Lead developer
- Uniquest
- Modality
- Small Molecules
01
Overview
Q-004 is a small molecule, allosteric inhibitor of caspase-1 (interleukin-1 beta-converting enzyme) being developed by the Queensland Emory Drug Discovery Initiative (QEDDI), a division of UniQuest (the commercialization company of the University of Queensland), in partnership with Emory University. Caspase-1 is an inflammatory protease that plays a critical role in the innate immune response by cleaving the inactive precursors of pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and interleukin-18 (IL-18), into their active mature forms, as well as initiating pyroptosis. Q-004 is currently in the lead optimization phase of development for the treatment of various inflammatory disorders.
02
Targets
CASP1 (Caspase-1)
Beyond the preview
Go deeper on Q-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Q-004.